Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Characterization of Tafamidis Non-Responders in Cardiac Amyloidosis: A Real-World Single-Centre Study
Session:
Sessão de Posters 15 - Prognóstico, estratificação de risco e comorbilidades na amiloidose cardíaca
Speaker:
Inês Brito E Cruz
Congress:
CPC 2026
Topic:
L. Cardiovascular Pharmacology
Theme:
31. Pharmacology and Pharmacotherapy
Subtheme:
31.1 Cardiovascular Pharmacotherapy
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Inês Brito E Cruz; Rita Bertão Ventura; Maria João Primo; Didier Martinez; Vanessa Lopes; João Rosa; Luís Leite; Maria João Ferreira; Lino Gonçalves
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Background: </strong>Tafamidis is the standard disease-modifying therapy for transthyretin cardiac amyloidosis, yet real-world cohorts show substantial heterogeneous treatment response. Characterizing non-responders may improve risk stratification, follow-up planning and therapeutic decision-making.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Purpose:</strong> To characterize Tafamidis non-responders at 12 months according to a composite definition integrating NYHA class, NT-proBNP, and echocardiographic parameters.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Methods: </strong>We conducted a single-centre observational study including 49 consecutive patients who initiated Tafamidis between Feb/2022 and Jun/2025. Non-response at 12 months was defined as ≥1 of the following: NYHA worsening, NT-proBNP rise ≥15%, or structural echocardiographic deterioration (LVEF decrease ≥5%, ≥1 mm wall-thickness increase, ≥2-point GLS worsening, or left atrial (LA) volume index increase ≥10 mL/m²). Tafamidis interruption, heart failure (HF) hospitalization and all-cause mortality were also evaluated.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Results: </strong>Twenty-four patients (49%) were non-responders (mean age 78.3±10.3 years, 75% male). Cardiovascular risk factors were highly prevalent: hypertension (83%), dyslipidaemia (58%), and atrial fibrillation (67%). Structural heart disease, predominantly moderate-to-severe aortic stenosis, was present in 13%. Baseline NYHA class was mainly II (62.5%), with median NT-proBNP of 2608.5 pg/mL (IQR 1600.5–4426.3). Baseline echocardiography demonstrated mean LVEF was 47.2% ± 12.1%, interventricular septal thickness 18.3 ± 3.0 mm, posterior wall 14.2 ± 2.3 mm, LA volume index 49.4 ± 12.5 mL/m² and E/e′ 16.0 ± 5.9. Median time from diagnosis to Tafamidis initiation was 94.5 days (IQR 39.5–259.8). After 12 months of treatment, one-third of patients demonstrated NYHA class deterioration, while NT-proBNP increased in 50%, with a median rise of 12.9% (IQR 10.2–29.4%). Echocardiographic progression occurred in 29% of reassessed patients, mainly due to LA enlargement. Overall, 8.3% discontinued Tafamidis owing to deterioration in functional or general status, 33.3% required HF hospitalization, and 12.5% died within 12 months.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Conclusion: </strong>Nearly half of the patients met criteria for non-response at 12 months, underscoring the need for improved patient selection. Non-responders showed an adverse profile characterized by advanced age, a high comorbidity burden, and high rates of short-term events. Additional research is necessary to clarify the implications of delayed treatment initiation. </span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site